Genentech has submitted a BLA to the FDA for trastuzumab-DM1 (T-DM1) to treat advanced HER2-positive breast cancer in patients that previously received multiple HER2-targeted medicines and chemotherapies. This submission is based on results from a Phase II study showing that T-DM1 shrank tumors in one-third of women who had received on average seven prior medicines for advanced HER2-positive breast cancer. The multi-center trial assessed single-agent T-DM1 in 110 women with HER2-positive adva...